Healthcare Private Placement and M&A Transactions Review Week Ending Jan 14, 2024

LB Pharmaceuticals: The company raised $110.7 million of venture funding from Pontifax Venture Capital and other undisclosed investors on January 10, 2024. The company is an operator of a drug development company intended to treat schizophrenia in patients.

Elephas: The company raised $51.2 million of Series C venture funding from undisclosed investors on January 8, 2024, putting the company’s pre-money valuation at $125 million. The company is an operator of a live tumor imaging diagnostics company intended to determine the proper cancer therapy for each patient.

Artisight: The company raised $42 million of Series B1 venture funding from Nvidia, GFT Ventures and Epsilon Health on January 11, 2024, putting the company’s pre-money valuation at $138 million. The company is a developer of an IoT sensor network designed to improve organizational operations and financial performance for healthcare.

Myrobalan Therapeutics: The company raised $24 million of Series A venture funding in a deal led by Co-Win Ventures on January 10, 2024. 3E Bioventures Capital, AB Magnitude Ventures Group and Guanzi Capital also participated in the round. The company is a developer of oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and Central Nervous System conditions.

Cambridge Medical Technologies: The company raised GBP 9.2 million of venture funding from Kayan Ventures and other undisclosed investors on January 10, 2024, putting the company’s pre-money valuation at GBP 45 million. The company is a manufacturer of medical devices designed to obtain clinical-grade readings of blood biomarkers.

Techcyte: The company raised $8.4 million of venture funding from undisclosed investors on January 10, 2024. The company is a developer of a cloud-based clinical digital pathology platform designed to help pathologists with the efficiency and accuracy of tests.

Transition Bio: The company raised $6 million of venture funding in the form of convertible debt from undisclosed investors on January 9, 2024. The company is an operator of a biotechnology company intended to build a hypothesis-free drug discovery and diagnostics platform.

XRHealth: The company raised $6 million of venture funding in a deal led by Asabys Partners on January 9, 2024. Clearbrook, and NOVA Prime Ventures also participated in the round. The company is an operator of a virtual health clinic intended to offer cognitive testing, pain management, and psychological assessment services.

SyntheX: The company raised $5.2 million of venture funding from undisclosed investors on January 10, 2024. The company is a developer of drug discovery platforms intended to use synthetic biology designed to modulate proteins.

Volta Labs: The company raised $4.3 million of venture funding from undisclosed investors on January 12, 2024. The company is an operator of a biological automation and affordable genomic sample preparation platform.

Impact Vitals: The company raised $2.7 million of venture funding in the form of convertible debt from undisclosed investors on January 12, 2024. The company is a developer of artificial intelligence-based medical technologies designed to transform basic physiologic data into vital signs.

Peytant Solutions: The company raised $2.5 million of venture funding in the form of convertible debt from undisclosed investors on January 10, 2024. The company is a developer of a medical implant designed to offer rapid bio-integration in the treatment of all luminal diseases.

SilkTech Biopharmaceuticals: The company raised $2.1 million of venture funding from undisclosed investors on January 11, 2024. The company is an operator of a biotechnology business intended to develop anti-inflammatory therapies.

Bolden Therapeutics: The company raised an undisclosed amount of venture funding from LifeSpan Vision Ventures on January 9, 2024. The company is an operator of a biotechnology company intended to improve the lives of patients suffering from neurodegeneration.

Cairn Therapeutics: The company is in the process of raising venture funding on January 11, 2024. The company is a developer of immunotherapeutic vaccines and targeted therapies intended to control tumor growth and recurrence.

MimiVax: The company raised an undisclosed amount of venture funding from Varia Ventures, The Brain Tumor Investment Fund and MEDA Angels on January 9, 2024. The Sontag Foundation and other undisclosed investors also participated in the round. The company is a developer of immunotherapeutic vaccines and targeted therapies intended to control tumor growth and recurrence.

Ambrx / Johnson & Johnson: The company reached a definitive agreement to be acquired by Johnson & Johnson for $2 billion on January 8, 2024. Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids into proteins within living cells.

Aiolos Bio / GSK: The company reached a definitive agreement to be acquired by GSK for $1 billion on January 9, 2024. The company is an operator of a clinical-stage biopharmaceutical business focused on the treatment needs of patients with respiratory and inflammatory conditions.

C2i Genomics / Veracyte: The company reached a definitive agreement to be acquired by Veracyte for an estimated $95 million on January 8, 2024. The company is a developer of a cancer treatment platform designed to improve patients’ lives and outcomes by monitoring cancer recurrence.

CoStim Pharmaceuticals / Polifin S.R.L.: The company was acquired by Polifin S.R.L. for EUR 75 million on January 11, 2024. The company is a developer of cancer immunotherapy.

Athersys / Healios: The company reached a definitive agreement to be acquired by Healios for an estimated $2 million on January 8, 2024. Athersys Inc is a biotechnology company engaged in the field of regenerative medicine.

Innersight / KARL STORZ: The company was acquired by KARL STORZ for an undisclosed amount on January 10, 2024. The company is a developer of a surgery planning platform intended to visualize cancer and improve surgery outcomes.